



FARE[®]

Clinical Development Day

Addressing Unmet Needs in Food Allergy:
Recent Advances, Ongoing Challenges,
and Prospects for the Future

October 17-18, 2024

Omni Shoreham Hotel
Washington, DC

A Letter from the CEO of FARE

Welcome to Clinical Development Day!

First, thank you for being here. Your presence speaks volumes about your commitment to advancing solutions for those with food allergy and their families. Food allergy affects people across every walk of life, every age, and all demographics. More than 33 million people in the U.S. live with this disease.

This third annual Clinical Development Day (CDD) represents a critical and extraordinary intersection of stakeholders in the realm of food allergy. The conversations that take place here will change the course of food allergy prevention, diagnosis, and treatment.

Our mission is to enable a world free from food allergy by providing transformative progress across our organization’s three pillars: research, education, and advocacy. We are also committed to health equity as an issue that underpins every pillar. Until the day a cure is not only available, but commonplace, FARE is committed to creating a more inclusive and supportive environment for all individuals living with food allergy.





The 2024 CDD is focused on “Addressing Unmet Needs,” and we recognize the gravity of that challenge. Food allergy is a top-tier public health issue. It’s personal for me, and for all of us at FARE. We can’t wait for solutions—we need them now. This gathering is an important part of identifying what comes next in our journey toward making the impossible possible.

We Are FARE,

Sung Poblete, PhD, RN
CEO of FARE

Highlights from the 2023 Clinical Development Day

The theme of last year’s Clinical Development Day (CDD) was “Barriers and Solutions to Optimal Food Allergy Prevention, Diagnostics, and Management Strategies.” Takeaways emphasized the need for continued innovation, accessible resources, and patient-centered approaches to advance the food allergy field.



Addressing Unmet Needs in Food Allergy: Recent Advances, Ongoing Challenges, and Prospects for the Future

Agenda for Thursday, October 17, 2024

Omni Shoreham Hotel

5:00 PM–6:00 PM	Cocktail Reception	Birdcage Walk
6:00 PM–7:00 PM	Dinner & Welcome <ul style="list-style-type: none">• Sung Poblete, PhD, RN, CEO of FARE (Food Allergy Research & Education)	Hampton Ballroom
7:00 PM–7:05 PM	Opening Remarks <ul style="list-style-type: none">• Stephen Tilles, MD, Research and Strategic Innovation Advisor of FARE (Food Allergy Research & Education)• Andrea Pappalardo, MD, University of Illinois Chicago	Hampton Ballroom
7:05 PM–8:05 PM	Bridging the Gap: Fostering Inclusive Innovation in Healthcare R&D <ul style="list-style-type: none">• Justine Asante, MS, LMFT, South Ward Promise Neighborhood• Amaziah Coleman, MD, National Institute of Allergy and Infectious Diseases, National Institutes of Health• Ruchi Gupta, MD, MPH, Northwestern Feinberg School of Medicine• Karen Jackler, MPH, U.S. Food and Drug Administration• Veronica Sandoval, PhD, JD, Genentech	Hampton Ballroom
8:05 PM–9:00 PM	Dessert Reception	Hampton Foyer

Agenda for Friday, October 18, 2024

Omni Shoreham Hotel

Our goal for the day is to identify and overcome the barriers that have hindered efforts to address the unmet needs in food allergy. The event is structured to foster meaningful discussion on three key topics: food allergy prevention, diagnostics, and therapeutics.

The agenda is divided into four main sessions, each led by one of the event's co-chairs or a special guest. Each session will begin with a concise 10-minute presentation to introduce the topic. Then, the presenter will join a panel of colleagues who represent diverse organizations and views. During the extended, interactive question and answer discussion that will follow, we encourage attendees to actively participate by asking questions and engaging with the panelists and fellow participants. This group includes leading scientists, industry experts, regulatory authorities, federal funders, and clinicians from across the world.

We look forward to everyone's contributions to this dialogue—because together, we can make a real difference for the 33 million people in the U.S. living with food allergy.

All sessions on October 18 take place in Hampton Ballroom

7:30 AM–8:00 AM

Continental Breakfast

8:00 AM–8:10 AM

Welcome & Opening Remarks

- Stephen Tilles, MD, FARE (Food Allergy Research & Education)
- Aikaterini (Katherine) Anagnostou, MD, PhD, Baylor College of Medicine
- Sarita Patil, MD, Harvard Medical School

Food Allergy Prevention: The Quest for Actionable Strategies to Enhance Awareness and Adoption

8:10 AM–9:10 AM

Introduction

- Ruchi Gupta, MD, MPH, Northwestern Feinberg School of Medicine

Panel Discussion

- Drew Bird, MD, University of Texas Southwestern
- Christina Ciaccio, MD, MSc, University of Chicago
- Marcus Shaker, MD, MSc, Dartmouth's Geisel School of Medicine
- Yamini Vikas Virkud, MD, MA, MPH, University of North Carolina at Chapel Hill
- *Moderator:* Aikaterini (Katherine) Anagnostou, MD, PhD

9:10 AM–9:15 AM

“Eat Early, Eat Often”

- Sung Poblete, PhD, RN, FARE (Food Allergy Research & Education)

Overcoming Barriers to the Development and Clinical Utilization of Food Allergy Diagnostics in the Pipeline

9:15 AM–10:15 AM

Introduction

- Pam Guerrerio, MD, PhD, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Panel Discussion

- Jean-Pierre Kinet, MD, ATANIS Biotech AG
- Ying (Katelin) Mao, PhD, U.S. Food and Drug Administration
- Geoffrey Mueller, PhD, National Institute of Environmental Health Sciences, National Institutes of Health
- Tibor Nemes, Stallergenes Greer
- Hugh Sampson, MD, Icahn School of Medicine at Mount Sinai
- *Moderator:* Sarita Patil, MD

10:15 AM–10:30 AM

Break

Therapeutics: What Will It Take to Achieve Disease Modification?

10:30 AM–11:30 AM

Introduction

- Alkis Togias, MD, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Panel Discussion

- Daniel Adelman, MD, University of California, San Francisco
- Tanya Laidlaw, MD, Harvard Medical School
- Rima Rachid, MD, Harvard Medical School
- Robert Wood, MD, Johns Hopkins University
- *Moderator:* Aikaterini (Katherine) Anagnostou, MD, PhD

Establishing a Framework for Enhancing the Development Pathway for Food Allergy Therapeutics: How Can Stakeholders Work Together to Get Treatments to the People Who Need Them?

11:30 AM–12:30 PM

Part 1: Early-Stage Assets and Therapies

Introduction

- James Baker, Jr., MD, University of Michigan

Panel Discussion

- Pascal Hickey, PhD, Aravax
- Adam Miller, JD, MBA, Allerfund
- Jessica O’Konek, PhD, University of Michigan
- Anubha Tripathi, MD, U.S. Food and Drug Administration
- *Moderator:* Stephen Tilles, MD

12:30 AM–1:00 PM

Break and Transition to Working Lunch

1:00 PM–2:10 PM

Part 2: Challenges in Standardization of Outcomes, Allergen Characterization, and Device Issues

Introduction

- Wayne Shreffler, MD, PhD, Harvard University

Panel Discussion

- Martin Chapman, PhD, InBio
- Pharis Mohideen, MD, MS, DBV Technologies
- Hendrik Nolte, MD, PhD, ALK-Abelló
- Ronald Rabin, MD, U.S. Food and Drug Administration
- *Moderator:* Stephen Tilles, MD

2:10 PM–3:20 PM

Part 3: Political, Economic, and Demographic Considerations

Introduction

- Brian Vickery, MD, Emory School of Medicine

Panel Discussion

- Vivian Hernandez-Trujillo, MD, Allergy & Immunology Care Center of South Florida
- Kelly Maples MD, American College of Allergy, Asthma & Immunology
- Michael Nelson, MD, PhD, American Board of Allergy and Immunology
- Benjamin Ortiz, MD, Novartis
- Anita Roach, MS, FARE (Food Allergy Research & Education)
- Paul Williams, MD, American Academy of Allergy, Asthma & Immunology
- *Moderator:* Brian Vickery, MD

Closing Remarks

3:20 PM–3:30 PM

Closing Remarks and Adjourn

- Stephen Tilles, MD

Biographies of Speakers

Daniel Adelman, MD

University of California, San Francisco

Dr. Adelman holds an academic appointment at the University of California, San Francisco as adjunct professor of medicine, and is a fellow of the American Academy of Allergy, Asthma & Immunology, the Clinical Immunology Society, and the American College of Physicians.



For over 25 years, Dr. Adelman has been developing novel therapeutics in the biotechnology industry in the San Francisco Bay Area. Dr. Adelman was Chief Medical Officer at Aimmune Therapeutics where he was responsible for leading the development of Palforzia®, the first treatment for patients with food allergies approved by the U.S. Food and Drug Administration and the European Medicines Agency. Prior to that he was Senior Vice President of Development and Chief Medical Officer at Alvine Pharmaceuticals Inc., a biotechnology company devoted to the development of a pharmaceutical treatment for celiac disease. Earlier in his career, Dr. Adelman was Senior Vice President, Development and Chief Medical Officer at Sunesis Pharmaceuticals, served in various roles at Pharmacyclics, including VP, Clinical Operations and Biometrics, and was a Clinical Scientist at Genentech where he led the early clinical development of two therapeutic monoclonal antibodies, Xolair® and Avastin®. Dr. Adelman has been involved in all stages of pharmaceutical drug development and is extensively published.

Dr. Adelman trained in internal medicine and was a clinical and research fellow at UCLA in the Division of Clinical Immunology and Allergy; he completed a National Institutes of Health/Public Health Service Tumor Immunology Fellowship. Dr. Adelman then took a position on the faculty at University of California, San Francisco, School of Medicine, where he was director of Clinical Allergy/Immunology in the Division of Allergy and Immunology, and director of the Outpatient Center for Clinical Research. He holds an AB degree in Biology from University of California, Berkeley and received his medical degree from the University of California, Davis.

Aikaterini (Katherine) Anagnostou, MD, PhD

Baylor College of Medicine, Texas Children's Hospital

Dr. Anagnostou is Professor of Pediatrics at Baylor College of Medicine and Texas Children's Hospital. She serves as director of the Food Immunotherapy Program, director of the Food Challenge Program, and co-director of the Food Allergy Program. She is also the lead for Adolescent Transition for Allergy.



Dr Anagnostou is passionate about investigating new and innovative treatments for food allergy. She has developed a strong interest in preventing and treating all forms of allergic disease and is committed to improving the quality of life of patients with allergies and their families.

Dr Anagnostou studied medicine at Aristotle University of Thessaloniki. She obtained her doctorate from the University of Cambridge in the United Kingdom. Her dissertation focused on two separate trials of peanut oral immunotherapy in children. Her research was published in *The Lancet* and received international recognition.

Justine Asante, MS, LMFT

South Ward Promise Neighborhood




Ms. Asante is Senior Director of Navigation and Partnerships for South Ward Promise Neighborhood (SWPN). In this role, she manages and oversees the Promise Navigation program which is a whole family system of care approach that supports families, from removing barriers to sustainability, assisting a family's journey towards education success, asset building, economic liberation, and achieving life's key milestones. She also manages partner relationships, provides partner technical assistance and coaching and facilitates cross-sector collaboration through SWPN's Collaborative Action Networks to achieve population systems level change and results.

Ms. Asante was born in and lived in Newark, New Jersey for 17 years. She is a Licensed Marriage and Family therapist who has over twelve years of experience working with children and families. She is dedicated to working with children and families from a multicultural, holistic approach which explores the different systems and relational aspects people are embedded in.

She obtained her bachelor's degree in psychology with a developmental focus from The College of New Jersey and her master's degree in Marriage and Family Therapy (MFT) from Seton Hall University. She uses her knowledge and skills from MFT professionals in her work collaborating with SWPN partners. Ms. Asante believes children and families have the innate ability to grow, change and overcome circumstances with the support and increase of protective factors which BRICK Network sets to provide.

James Baker, Jr., MD

University of Michigan



Dr. James Baker is the founding Director of the Mary H. Weiser Food Allergy Center and the Ruth Dow Doan Professor of Biologic Nanotechnology at Michigan Medicine. His academic and commercial accomplishments are varied and relevant to the development of drugs for food allergy. He is a Professor of Biomedical Engineering in the College of Engineering at the University and the Director of the Michigan Nanotechnology Institute for Medicine and Biological Sciences. He is a past SVP at Merck where he was global head of the vaccine franchise. He is also the former CEO of FARE from 2014–2018. Dr. Baker's research is in the area of immunology and host defense, evolving into nanomaterials and their applications in therapeutics. He has invented several forms of synthetic lipid and polymeric nanostructures, which have resulted in the development of new approaches to therapeutic molecules and vaccines. He also has extensive drug development experience having taken several therapeutics from the laboratory through Phase III clinical trials. At Merck he oversaw the development of the GARDASIL and VAXNEUVANCE™ vaccines.

Dr. Baker graduated from Loyola University with his medical degree and completed clinical training in allergy and immunology at Walter Reed Army Medical Center.

J. Andrew (Drew) Bird, MD

University of Texas Southwestern

Dr. Bird joined the faculty at UT Southwestern in Dallas in 2009. He is Professor of Pediatrics and Internal Medicine in the Division of Allergy and Immunology, director of the Food Allergy Center at Children's Medical Center, and interim division chief of the Division of Allergy and Immunology at UT Southwestern. His clinical and research interests focus on food allergy diagnosis and in understanding and treating life-threatening reactions to foods.



Dr. Bird received his medical degree from the University of Texas Medical School in San Antonio. He completed a pediatrics residency at Baylor College of Medicine, where he also finished his advanced training with a fellowship in allergy and immunology. He was the first recipient of the American Academy of Allergy, Asthma, and Immunology/Food Allergy Initiative Howard Gittis Memorial Award, which allowed him to complete a clinical research fellowship in food allergy under the direction of Dr. Wesley Burks at Duke University.

Martin Chapman, PhD

InBio

Dr. Chapman is President and Chief Executive Officer of InBio (formerly Indoor Biotechnologies), a privately held biomanufacturing company that specializes in the production of allergens and other biologics for research and diagnostics. Prior to founding InBio, he was a tenured Professor of Medicine and Microbiology at the University of Virginia.



For more than 40 years, Dr. Chapman has pioneered research focused on the molecular properties of allergens and their role in causing allergic diseases, such as asthma and food allergy. His work led to determining the structures of important allergens and the development of innovative tests for measuring allergens in homes, schools and workplaces. Dr. Chapman's latest research involves gene editing of cat allergen using CRISPR.

He has published over 280 peer-reviewed articles, reviews, and book chapters. He is the recipient of numerous National Institutes of Health grants and served on the editorial boards of allergy and immunology journals. Dr. Chapman is a Fellow of the American Academy of Allergy, Asthma & Immunology. He received his doctorate in Immunology from the Royal Postgraduate Medical School, University of London, UK.

Christina Ciaccio, MD, MSc

University of Chicago

Dr. Christina Ciaccio is Professor of Pediatrics and Medicine at the University of Chicago and Chief of the Section of Allergy/Immunology and Pediatric Pulmonology. Dr. Ciaccio currently serves as the Director of the University of Chicago Center for Food Allergy Care, Education, and Translational Research (FACET) and has a research interest in understanding how nutrition and microbial exposures influence IgE sensitization as well as improving allergy diagnostic testing. Her work has been funded by both the NIH and foundation support. She has overseen over 20 clinical trials and has authored over 50 peer-reviewed publications.



Dr. Ciaccio earned a bachelor's degree in mathematics from Notre Dame and her medical degree from Georgetown University. She completed her clinical training with an internal medicine residency and an Allergy and Immunology Fellowship at McGaw Medical Center at Northwestern. She also holds a master's degree in clinical research from the University of Kansas.

Amaziah Coleman, MD

National Institute of Allergy & Infectious Disease (NIAID), National Institutes of Health (NIH)



Amaziah Coleman, MD, MBA, has served as a Medical Officer/Physician in the Allergy, Asthma and Airway Biology Branch (AAABB) within the Division of Allergy, Immunology and Transplantation (DAIT) at NIAID since 2021. She received her medical degree from the University of Mississippi Medical Center and completed her pediatric residency at the University of Arkansas/Arkansas Children's Hospital, followed by a postdoctoral fellowship in allergy and immunology at the University of Wisconsin School of Medicine and Public Health. In 2016, she was appointed Assistant Professor of Pediatrics at the George Washington University School of Medicine and Health Sciences and Attending Physician at Children's National Hospital, in Washington, D.C. Dr. Coleman has conducted original research in pediatric asthma and food allergy with many of her publications and presentations focused on diversity research related to these conditions. Dr. Coleman is currently leading studies in the Childhood Asthma in Urban Settings (CAUSE) consortium, the Atopic Dermatitis Research Network (ADRN) and the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). She additionally leads a small business clinical trial focused on innovative treatment for food allergy. Dr. Coleman has expertise in health equity leadership and improving representation in clinical research studies.

Pamela Guerrero, MD, PhD

National Institute of Allergy & Infectious Disease (NIAID), National Institutes of Health (NIH)



Dr. Guerrero is currently Chief of the Food Allergy Research Section and the Laboratory of Allergic Diseases at NIH. Her research program is focused on understanding the genetic and immunologic mechanisms that lead to food allergy, eosinophilic esophagitis, and related diseases, and identifying strategies to improve the care of these patients.

She received her medical degree and doctorate in human genetics from Johns Hopkins University where she also completed a residency in pediatrics and fellowship in allergy and immunology.

Ruchi Gupta, MD, MPH

Northwestern Feinberg School of Medicine



Dr. Gupta is a Professor of Pediatrics and Medicine at Northwestern University Feinberg School of Medicine and a Clinical Attending at Ann & Robert H. Lurie Children's Hospital of Chicago. Dr. Gupta has 20 years of experience as a board-certified pediatrician and health researcher and currently serves as the founding director of the Center for Food Allergy & Asthma Research. She is world-renowned for her groundbreaking research in the areas of food allergy and asthma epidemiology, most notably for her research on the prevalence of pediatric and adult food allergy in the United States. She has also significantly contributed to academic research in the areas of food allergy prevention, socioeconomic disparities in care, and the daily management of these conditions. To reduce the burden of these diseases and improve health equity, she and her team develop, evaluate, and disseminate interventions for families and conduct work to inform local, national, and international health policy.

Dr. Gupta is the author of *The Food Allergy Experience* and *Food Without Fear*, has written and co-authored over 200 peer-reviewed research manuscripts, and has had her work featured on major television networks and in print media.

She attended medical school at the University of Louisville and completed a residency in pediatrics at the University of Washington Hospital. She went on to obtain a master's degree in public health from Harvard Medical School.

Vivian Hernandez-Trujillo, MD

Allergy and Immunology Care Center of South Florida

Dr. Hernandez-Trujillo is founder of Allergy and Immunology Care Center of South Florida, Medical Director of the Division of Allergy and Immunology at Nicklaus Children's Hospital, and Clinical Professor of Pediatrics at Florida International University.



Her current interests are focused on healthcare disparities, particularly the impact on Hispanic/Latinx patients. Additionally, she has also led several efforts to increase early solid food introduction in infants, in collaboration with the American Academy of Pediatrics.

Dr. Hernandez-Trujillo has served on committees for many national organizations including the American Academy of Pediatrics Section of Allergy and Immunology, the Council of Pediatric Subspecialties for the American College of Allergy, Asthma & Immunology, and the Immune Deficiency Foundation Medical Advisory Board. She has conducted basic laboratory research and served as an investigator on numerous clinical studies. She has published multiple articles in respected medical journals and lectures nationally and internationally on the topics of pediatric food allergy, anaphylaxis, and immunodeficiency.

Dr. Hernandez-Trujillo received her medical degree from Albany Medical College, New York. She completed a pediatric residency at Miami Children's Hospital followed by an allergy and immunology fellowship at the University of Tennessee, Memphis, St. Jude Children's Research Hospital and Le Bonheur Children's Hospital.

Pascal Hickey, PhD

Aravax

Dr. Hickey is currently Chief Executive Officer of Aravax, a clinical-stage biotechnology company based in Australia. He has nearly 30 years' experience in biotech industry research and development across Europe, North America and Australia, holding functional leadership roles in nonclinical, formulation, delivery systems, manufacturing and clinical development for various product classes. He has worked in many therapeutic areas including pain, osteoporosis, diabetes, autoimmune disease, infectious disease, asthma and allergy. He is passionate about developing people and building organizations to meet the challenge of leveraging innovative technologies to create new and improved medicines.



Dr. Hickey is a member of the European Academy of Allergy and Clinical Immunology, and Australia's Biotechnology Association. He is a registered pharmacist with a doctorate in Pharmaceutical Science from Monash University, and a graduate of the Australian Institute of Company Directors.

Karen Jackler, MPH

Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA)



Ms. Jackler is the program manager for CBER's Patient Engagement Program. She works with patient organizations and FDA colleagues to coordinate patient engagement activities and to facilitate information sharing and collaboration. Prior to joining CBER in 2018, she served as a strategic communication advisor and project manager for the FDA Center for Drug Evaluation and Research and the FDA Center for Devices and Radiological Health. Her experience also includes communication research and outreach roles with the National Institutes of Health and the Centers for Disease Control and Prevention.

Ms. Jackler holds a Master of Public Health with a concentration in Health Communication and Education and a Bachelor of Science in Cellular and Molecular Biology; both degrees are from Tulane University.

Jean-Pierre Kinet, MD

ATANIS Biotech



Dr. Kinet is Co-Founder and Chief Executive Officer of ATANIS Biotech, which was established in 2019 to develop a novel, functional cell-based assay for diagnosing allergies and predicting treatment success of therapies. He also serves as managing partner of iXLife Capital and is a professor emeritus at Harvard Medical School.

Dr. Kinet is credited for the cloning, identification and structural, biochemical and functional characterization of the tetrameric high affinity immunoglobulin E receptor (FcεRI) and the discovery that one of its units, known as FcRγ, is part of other receptors. In addition, he identified three novel ion channels including the genetic identification of the elusive CRAC channel, the channel responsible for calcium entry in immune cells such as mast cells.

He has authored more than 200 scientific publications and holds numerous patents. He completed his medical training at the University of Liège, followed by a post-doctoral fellowship at the National Institutes of Health.

Tanya Laidlaw, MD

Harvard Medical School, Brigham and Women's Hospital



Dr. Laidlaw is an Associate Professor of Medicine at Harvard Medical School, in the Division of Allergy and Clinical Immunology at Brigham and Women's Hospital (BWH), where she is director of the Aspirin-Exacerbated Respiratory Disease (AERD) Center and Chief of the Section of Clinical and Translational Sciences. She also serves as Deputy Director of the National Institutes of Health Immune Tolerance Network, an international consortium of basic scientists and clinical investigators that perform clinical research to evaluate the safety and efficacy of methods that can induce the immune system to tolerate certain antigens for the treatment of immune-mediated disorders.

Dr Laidlaw's research and clinical expertise focuses on patients with severe asthma, chronic rhinosinusitis with nasal polyps, respiratory inflammation, and other type 2 inflammatory disorders, with the goal of understanding the causative mechanisms for these diseases and exploring new treatments. She has published over 100 peer-reviewed articles, and her research findings have appeared in journals such as *The New England Journal of Medicine*, *Nature*, *Blood*, *The Journal of Allergy and Clinical Immunology*, and *Annals of Allergy, Asthma & Immunology*. Dr. Laidlaw earned her medical degree from the University of Massachusetts Medical School. She completed a residency in pediatrics at Massachusetts General Hospital and an allergy/immunology fellowship at BWH.

Ying (Katelin) Mao, PhD, MSc

Center for Devices and Radiological Health, U.S. Food and Drug Administration (FDA)

Dr. Mao serves as Chief of the Immunology and Flow Cytometry Branch, Division of Immunology and Hematology Devices, within the Office of In Vitro Diagnostics, where she is responsible for overseeing the evaluation and regulation of in vitro diagnostic medical devices in the areas of: allergy, autoimmune diseases, neurological disorders, blood-based cancer biomarkers, flow cytometry, generic health risk assessment, companion diagnostics, and more, ensuring they meet safety and effectiveness standards. Prior to joining FDA, Dr. Mao gained extensive academic and industry experiences in microbial genetics, infectious diseases, vaccine development, and assay development.



Dr. Mao earned her Master of Science from Oklahoma State University and received her doctorate from Purdue University.

Kelly Maples, MD

Eastern Virginia Medical School

Dr. Maples is Professor of Pediatrics and Internal Medicine at Eastern Virginia Medical School (EVMS) and practices allergy/immunology at the Children's Hospital of The King's Daughters.



She has held national leadership positions including a 3-year term on the Board of Regents of the American College of Allergy, Asthma & Immunology (ACAAI), and a one-year term on the ACAAI Executive Committee. She currently holds the position of ACAAI Treasurer.

She received bachelor's degrees in biological sciences and psychology from Rutgers University and attended Temple University for medical school. She completed residency training at EVMS, followed by an allergy and immunology fellowship at Virginia Commonwealth University.

Adam Miller, JD, MBA

Allerfund

Mr. Miller, an avid social entrepreneur and philanthropist, began his career as an investment banker and consultant. From his one-bedroom apartment, he founded and served as Chief Executive Officer of Cornerstone OnDemand, Inc., a cloud-based development software provider and learning technology. Among his current roles, he is managing partner of 1P Ventures, 1P Impact Capital, and Allerfund, the first venture fund dedicated to food allergy.



In support of the food allergy community, he led the merger of Food Allergy & Anaphylaxis Network (FAAN) and Food Allergy Initiative (FAI) to create FARE, seeded Aimmune Therapeutics, which developed the first FDA-approved treatment for food allergies, and helped build a food allergy program at the University of California, Los Angeles (UCLA).

Mr. Miller earned bachelor's degrees in history and economics from the University of Pennsylvania and received his law degree and Master of Business Administration from UCLA.

Pharis Mohideen, MD, MS

DBV Technologies

Dr. Mohideen serves as Chief Medical Officer and is a member of DBV's executive committee, responsible for continuing development efforts of the company's pipeline and bringing potentially innovative new treatments to patients, if approved. Dr. Mohideen brings nearly two decades of industry experience and a track record of multiple drug product approvals. Prior to joining DBV, Dr. Mohideen served as Chief Medical Officer for Millendo Therapeutics, Inc., Vice President of Clinical Development at Shionogi Inc., and other clinical and medical leadership roles with Novartis International AG and Bristol Myers Squibb. Prior to joining the pharmaceutical industry, Dr. Mohideen was an attending physician and assistant professor of Medicine at the University of Hawaii, Department of Internal Medicine, and served as an investigator on multiple pharmaceutical-sponsored clinical trials.



Dr. Mohideen received his medical degree as well as a Master of Science in human biology from the University of Hawaii. Additionally, he holds a graduate degree in clinical investigation from Vanderbilt University.

Geoffrey Mueller, PhD

National Institute of Environmental Health Sciences, National Institutes of Health

Dr. Mueller is Director of the Nuclear Magnetic Resonance (NMR) Research Core Facility and Principal Investigator at the National Institute of Environmental Health Sciences. His independent research focuses on the molecular determinants of allergic disease, and he currently serves as Secretary of the Allergen Nomenclature Sub-committee within the World Health Organization and International Union of Immunological Societies. An expert in NMR, structural biology, and molecular allergology, he has more than 150 peer-reviewed publications to his credit.



Dr. Mueller completed his undergraduate studies at the College of William and Mary. He earned his doctorate in biophysics from the University of Virginia and completed a postdoctoral fellowship at the University of Toronto.

Michael Nelson, MD, PhD

University of Virginia

Dr. Nelson is the Andrew D. Hart Professor of Medicine and Chief of the Division of Asthma, Allergy, and Clinical Immunology at the University of Virginia (UVA) and president-elect and Chief Executive Officer of the American Board of Allergy and Immunology, the premier organization certifying allergists and immunologists nationwide. Prior to joining UVA, he served more than 25 years in the U.S. Army and leadership in Walter Reed National Military Medical Center, the Uniformed Services University of Health Sciences, and the U.S. Army Office of the Surgeon General.



Dr. Nelson has consistently advocated for the specialty of allergy and immunology on a national scale, serving on committees and task forces with the Accreditation Council for Graduate Medical Education, the U.S. Food and Drug Administration, the American Medical Association and more. He is a national expert in the evidenced-based practice of allergen immunotherapy and allergen extract preparation, publishing numerous manuscripts including multiple national practice parameters. His most recent research interest has focused on vaccine immune response and rare adverse effects.

Dr. Nelson earned his medical degree and doctorate in pharmacology at UVA followed by an internal medicine residency at Eisenhower Army Medical Center. He then pursued fellowships in Allergy-Immunology and Clinical Laboratory Immunology at Walter Reed Army Medical Center.

Tibor Nemes, BS

Stallergenes Greer

Mr. Nemes currently serves as Executive Vice President, Head of the Americas, and President of Stallergenes Greer, Inc. During his 25-year career in the biotech and pharmaceutical industry, he has held leadership positions with Novartis, Novavax, Bristol Myers Squibb, and Elan Pharmaceuticals. He has extensive technical experience in biopharmaceutical engineering, product development, quality assurance, and the manufacturing of biologics, vaccines, cyto-toxic oncology, and other sterile products. He has been involved in the commercialization of an array of biologics and vaccines throughout his career.



Mr. Nemes holds a bachelor's degree in chemical engineering from Pennsylvania State University and completed executive studies in leadership development from Harvard Business School.

Hendrick Nolte, MD, PhD

ALK-Abelló

Dr. Nolte is Senior Vice President of clinical development of allergy immunotherapy tablets and other global drug developments for respiratory related products/projects for ALK-Abelló. Prior to this role, he led early and late stage respiratory and clinical research at Roche, Schering-Plough, and Merck. He also previously served as an associate professor of medicine at the University of Copenhagen.



Dr. Nolte has served on the U.S. Food and Drug Administration Vaccine Products Advisory Committee and on the Allergenic Products Advisory Committee. He has published extensively within the field of allergy and asthma with more than 200 peer-reviewed publications and given more than 1,000 lectures at international meetings. He is a fellow of the American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology. He received his medical and postdoctoral degrees from the University of Copenhagen and is board-certified in pulmonology, internal medicine, and trained in allergy.

Jessica O'Konek, PhD

University of Michigan

Dr. O'Konek is an Assistant Professor in the Mary H. Weiser Food Allergy Center at the University of Michigan where she studies innate immune activation and immune modulation by vaccine adjuvants. Her current research focuses on utilizing vaccine-based approaches to modulate food allergy immune responses while determining the immunological mechanisms of action of these adjuvants in shifting pre-existing immune responses. Her lab has a strong interest in the development of animal models for food allergy and has strong collaborations with industry partners for pre-clinical testing to aid in the development of therapeutics. Her work aims to understand the immune pathways that mediate food allergy with the goal of developing new therapies to both treat and prevent food allergy. She earned her doctorate in pharmacology from the University of Michigan and completed postdoctoral training in the Vaccine Branch of the National Cancer Institute at the National Institutes of Health where she further specialized in immunology and vaccine development.



Benjamin Ortiz, MD

Novartis Pharmaceuticals Corporation

Dr. Ortiz is Senior Clinical Development Medical Director in the immunology unit of Novartis Pharmaceuticals Corporation. During his tenure within the pharmaceutical industry, he supported the development of Xolair®, leading to regulatory approval for the indications of chronic spontaneous urticaria, asthma, chronic rhinosinusitis with nasal polyps, and food allergy. While at Sanofi and Regeneron, he worked on the Dupilumab® respiratory and allergy programs. He spent two years as a Medical Officer and Special Government Employee at the U.S. Food and Drug Administration, expanding the Office of Pediatric Therapeutics Latin American regulatory program. Additionally, he practiced academic medicine for nearly a decade where he led pediatric asthma programs.



Dr. Ortiz earned a bachelor's degree in biochemistry at Columbia University before completing medical school and a pediatric residency at Icahn School of Medicine at Mount Sinai. He remains an active member and Fellow of the American Academy of Pediatrics.

Andrea Pappalardo, MD

University of Illinois Chicago

Dr. Pappalardo is Associate Professor of Medicine and Pediatrics at the University of Illinois Chicago. She is board certified in three specialties: internal medicine, pediatrics and allergy/immunology and serves as the Allergy Service Director. Dr. Pappalardo recently served as the Medical Director for the Mobile Care Chicago Asthma Vans, where she provided school-based asthma and allergy subspecialty care throughout greater Chicago in front of schools. Her research focuses on school and community-engaged implementation science-driven interventions to reduce health disparities in asthma and food allergy. She believes strongly in increasing sub-specialty access in historically marginalized populations in allergic diseases and in promoting health equity throughout the United States. Her work in stock inhaler legislation and programming is recognized locally and nationally.



Dr. Pappalardo attended medical school at the University of Illinois Chicago, followed by a combined internal medicine and pediatrics residency at the University of Chicago. She completed an allergy and immunology fellowship at Rush University Medical Center.

Sarita Patil, MD

Harvard Medical School, Massachusetts General Hospital

Dr. Patil is an Assistant Professor at Harvard Medical School and an Assistant in Medicine at Massachusetts General Hospital (MGH). She is Co-Director of the MGH Adult Eosinophilic Esophagitis Clinic and a member of the MGH Food Allergy Center. Her laboratory, in the Center for Immunology and Inflammatory Diseases, focuses on understanding antibody and B cell responses in both the initiation and treatment of allergic diseases, with a particular focus on food allergies. She is the incoming co-Chair of the 2026 Food Allergy Gordon Research Conference and Mechanistic Co-Chair of a trial sponsored by the Immune Tolerance Network. Dr. Patil earned a bachelor's in human biology with honors from Stanford University and her medical degree from Duke University, which included a Howard Hughes Medical Research Fellowship. She completed her clinical training with an internal medicine residency at the University of Pennsylvania followed by an allergy and immunology fellowship at MGH.



Sung Poblete, PhD, RN

FARE (Food Allergy Research & Education)

Sung Poblete, PhD, RN, is the Chief Executive Officer of FARE. Prior to joining FARE in 2022, she served as CEO of Stand Up To Cancer (SU2C) for more than a decade. Early in her career, she held executive positions with a focus on patient outcomes and disease management. Notably, as vice president of clinical operations for a subsidiary of Fresenius Medical Care North America, she developed and implemented a national chronic kidney disease management program. As executive director of the Oxford Health Plans Foundation, she facilitated grants that furthered research and programs aimed at improving health care delivery. She currently serves as a member of the Board of Directors for Apricity Health, UbiVac, Proteus, Osteosarcoma Institute, and the Pacific Pediatric Neuro-Oncology Consortium (PNOC), and she is on the advisory board of Nok Nok and Medically Home.



Dr. Poblete has been the recipient of numerous high-level research funding grants from the Centers for Disease Control and Prevention, National Institutes of Health, National Science Foundation, and private foundations. She earned her Bachelor of Science and Master of Science degrees, as well as a doctorate in nursing, from Rutgers, The State University of New Jersey, which honored her with a 2016 induction into the Rutgers Hall of Distinguished Alumni.

Ronald Rabin, MD

Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Dr. Rabin is chief of the Laboratory of Immunobiochemistry (LIB), Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. Within the LIB, Dr. Rabin supervises the reference reagent laboratory to ensure proper potency measurements of standardized allergen extracts and the evaluation of “chemistry, manufacturing, and controls (CMC)” of allergenic products that are in clinical studies or under consideration for licensure. Additionally, Dr. Rabin was the primary clinical reviewer for the first sublingual immunotherapy products approved for grass and ragweed allergies. Dr. Rabin received his medical degree at the University of South Florida College of Medicine, completed his residency in pediatrics at the University of Kentucky, and his fellowship in allergy and immunology at the National Institute of Allergy and Infectious Diseases.



Rima Rachid, MD

Harvard Medical School, Boston Children’s Hospital

Dr. Rachid is Director of Allergen Immunotherapy and co-director of the Food Allergy Program at Boston Children’s Hospital (BCH) and an associate professor of pediatrics at Harvard Medical School. As a clinician researcher, she has led multiple interventional trials evaluating novel therapies for food allergy. An expert in the microbiome, her studies demonstrated ongoing dysbiosis in children with food allergy, which led to discoveries that small bacterial consortia can prevent or treat the disease in mice. Dr. Rachid led the first trial in the world to evaluate the role of fecal microbiota transplantation in food allergy. Her work has been published in cutting-edge journals including Nature Medicine, The New England Journal of Medicine, Immunity and the Journal of Allergy and Clinical Immunology. She is co-inventor on four patents targeting the treatment and prevention of food allergy and anaphylaxis.



Dr. Rachid studied at the American University of Beirut and completed allergy and immunology training at BCH.

Anita Roach, MS

FARE (Food Allergy Research & Education)

As Vice President of Health Equity and Community Engagement, Anita supports FARE's efforts to understand unmet needs at the neighborhood level, provide community-powered food allergy education, awareness and support, and create pathways for improved representation in research and care. Anita also serves as FARE's Principal Investigator on a Eugene Washington Patient-Centered Outcomes Research Initiative Award project addressing barriers to treatment and prevention strategies for people facing food allergies in Black and under-resourced communities in Washington, D.C.



Anita is skilled at communicating complex and technical information to patient and professional communities. She has several publications in *The Journal of Clinical Immunology: In Practice*, *Arthritis & Rheumatology*, and *Sleep Health*. She was also a Health Equity Instructor for the 2023 Annual Allergy, Asthma, & Immunology Meeting.

Ms. Roach earned a bachelor's degree in molecular biology and microbiology from the University of Central Florida and graduated *magna cum laude* from Georgetown University with a master's degree in biochemistry and molecular biology.

Hugh Sampson, MD

Icahn School of Medicine at Mount Sinai

Dr. Sampson is the Kurt Hirschhorn Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai and director emeritus of the Jaffe Food Allergy Institute. Dr. Sampson's research interests have focused on food allergic disorders, and now include work on the pathogenesis of food-induced anaphylaxis, characterization of allergenic food proteins and their processing by the immune system, genetics of food allergy, development of novel diagnostic tests, and mechanisms of immunotherapeutic strategies for treating food allergies, including basic studies and clinical trials in oral, sublingual, and epicutaneous immunotherapy, and the potential use of biologics, such as anti-IgE and anti-cytokine monoclonal antibodies. He is the recipient of numerous grants from the National Institutes of Health, including the recently funded Exposure to Vaginal Microbiome in C-section Infants at High-risk for Allergies – A Pilot Study. Dr. Sampson supervises one clinic a week in pediatric allergy and is involved in teaching fellows and residents. He is past president of the American Academy of Allergy, Asthma & Immunology, past chair of the Section on Allergy & Immunology of the American Academy of Pediatrics, and a member of the National Academy of Medicine. He has authored more than 500 publications and has a current h-index of 154.



He received his medical degree from University at Buffalo School of Medicine, completed his pediatric residency at Northwestern University, and his allergy/immunology fellowship at Duke University.

Veronica Sandoval, PhD, JD

Genentech

Dr. Sandoval is a Principal in the Patient Inclusion and Health Equity team in the Chief Diversity Office at Genentech. Her extensive background in policy, medical affairs, and her personal and professional connection to her Latino heritage enrich Genentech's ongoing initiatives in health equity and inclusive research. Since joining Roche-Genentech in 2018 as a Global Medical Collaboration Lead for autism clinical development, Dr. Sandoval has held pivotal roles, including supporting the respiratory portfolio as a Medical Science Liaison and leading Genentech's corporate health equity strategy.



Her career spans health equity, medical affairs, thought leader development, patient engagement, and fostering external partnerships. She brings expertise across a wide array of therapeutic areas, including ophthalmology, oncology, multiple sclerosis, immunology, asthma, inflammatory bowel disease, women's health, autism spectrum disorder, idiopathic pulmonary fibrosis, and influenza. Additionally, Dr. Sandoval practiced as an intellectual property litigation attorney focusing on complex patent litigation in the life sciences and pharmaceutical fields.

Dr. Sandoval holds a doctorate in neuropharmacology from the University of Utah, a Doctor of Jurisprudence from Seattle University School of Law, and a bachelor's degree in molecular and cell biology from the University of California, Berkeley.

Marcus Shaker, MD, MSc

Dartmouth's Geisel School of Medicine

Dr. Shaker is a Professor of Pediatrics and of Medicine at the Dartmouth Geisel School of Medicine, and a member of the Allergy Immunology Joint Task Force on Practice Parameters. Dr. Shaker is also an Associate Editor of *Annals of Allergy, Asthma, & Immunology* and an Editorial Board member of *The Journal of Allergy and Clinical Immunology: In Practice*. Dr. Shaker's research interests center around optimizing value-based care in allergy and clinical immunology. He has published over 200 articles and guidelines.



Dr. Shaker attended medical school at the University of Virginia and completed his pediatric residency and fellowship training in allergy and immunology, both at the University of Virginia Health System. He also holds a master's degree in evaluative clinical sciences and healthcare leadership.

Wayne Shreffler, MD, PhD

Harvard Medical School, Massachusetts General Hospital

Dr. Shreffler is Chief of Pediatric Allergy & Immunology and Director of the Food Allergy Center at Massachusetts General Hospital (MGH), and an Investigator at the Center for Immunology and Inflammatory Disease as well as the Food Allergy Science Initiative. Since joining MGH in 2010, he has developed a highly integrated research and clinical program to better understand how adaptive immunity to dietary antigens is both naturally regulated and modulated by therapy in the context of food allergy.



Dr. Shreffler has authored more than 70 papers, maintained continuous research funding since 2007, served on the editorial board of *The Journal of Allergy and Clinical Immunology* and as a reviewer for numerous journals and grant study sections/committees. He was elected a Fellow of the American Academy of Allergy, Asthma & Immunology.

He received his medical and doctorate degrees from New York University and his Pediatrics training at the Albert Einstein College of Medicine. He completed his fellowship in Allergy & Immunology at the Mount Sinai School of Medicine.

Stephen Tilles, MD

FARE (Food Allergy Research & Education)



With nearly thirty years of experience in both clinical practice and the pharmaceutical industry, Dr. Tilles recently established a consulting firm focused on overcoming obstacles for food allergy patients to access innovative solutions. He currently serves as FARE's Research and Strategic Innovation Advisor, and as clinical professor of Medicine at the University of Washington. He also serves as a consultant to Stallergenes Greer, Inc.

His previous roles include serving as Head, Global Medical Affairs, Allergy at Aimmune Therapeutics; president of the American College of Allergy, Asthma & Immunology; assistant professor of Medicine and Pediatrics and director of the Allergy and Asthma Clinic at Oregon Health Sciences University (OHSU); and service on both the Joint Task Force for Practice Parameters and the American Board of Allergy and Immunology.

Dr. Tilles was previously a partner at the Northwest Asthma and Allergy Clinic in Seattle, WA, and executive director of ASTHMA Inc, a non-profit clinical research center. He served as principal investigator for more than 140 clinical trials involving treatments for asthma, allergic rhinitis, urticaria and atopic dermatitis, as well as 13 trials evaluating treatments for food allergy. He has authored more than 100 papers in peer-reviewed publications.

His educational background includes a bachelor's degree from Harvard College, a medical degree from the University of California San Diego School of Medicine, internal medicine residency training at OHSU, and fellowship training in allergy and immunology at the National Jewish Center for Immunology and Respiratory Medicine.

Alkis Togias, MD

National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH)



Dr. Togias is the chief of the Allergy, Asthma and Airway Biology Branch at the Division of Allergy, Immunology and Transplantation of the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health. His responsibility is to supervise the stewardship of all NIAID-funded grants and programs, as well as the scientific research initiatives in allergic diseases, asthma, and inflammatory upper airway conditions. This includes the NIAID-funded clinical networks Childhood Asthma in Urban Settings (CAUSE), Consortium for Food Allergy Research (CoFAR), Atopic Dermatitis Research Network (ADRN), Asthma and Allergic Diseases Cooperative Research Centers (AACRC), and the allergy projects of the Immune Tolerance Network (ITN), as well as investigator-initiated clinical trials and investigator-initiated research project grants. Dr. Togias also co-directs the NIAID-funded Human Immunology Project Consortium (HIPC) and is a project scientist in the Airways Workgroup of the NIH-funded Environmental Influences on Child Health Outcomes (ECHO) initiative.

Dr. Togias earned his medical degree at the National and Kapodistrian University of Athens, Greece, and received his post-doctoral research and clinical training in medicine and then in allergy and clinical immunology at The Johns Hopkins Hospital and Johns Hopkins University. He was on faculty at Johns Hopkins University from 1989 to 2006, when he joined the NIH.

Anubha Tripathi, MD

Center for Biologics Evaluation and Research, U.S. Food and Drug Administration (FDA)



Dr. Tripathi conducts clinical review for FDA's Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Clinical and Toxicology Review, as a physician subspecialized in the field of allergy and clinical immunology. While her current role is primarily focused on the comprehensive evaluation of clinical development programs, including evaluation of safety and effectiveness data for investigational allergenic, vaccine, and related biological therapeutic products, she is also extensively involved in other aspects of this role. These include authoring publications in subspecialty medical journals and books including *JACI* and the *Encyclopedia of Food Allergy*; presenting to and discussing relevant regulatory information with various external subspecialty organizations including AAAAI, Paul Ehrlich Institute, APMA, and FARE; and aiding in the development of policy and of FDA workshops on various topics of importance to the field of allergy and clinical immunology.

After completing her residency training in internal medicine at Tufts Medical Center, Dr. Tripathi served as an attending physician in both hospital and medical practice settings. She completed her clinical and research fellowship in allergy and clinical immunology in the University of Virginia Health System's Division of Allergy and Clinical Immunology, where she also served on faculty as an Assistant Professor in Medicine. During her tenure, she served as both a principal, co-, and sub-investigator in clinical trials and research studies investigating various food allergies and eosinophilic esophagitis. She also authored several publications in these areas in various books and medical journals including *JACI* and *JACI: In Practice* and presented her research findings in these areas at the annual meetings of numerous medical subspecialty organizations including those of the American Academy of Asthma, Allergy & Immunology, the American College of Asthma, Allergy & Immunology, the European Academy of Allergy & Clinical Immunology, and Digestive Disease Week.

Brian Vickery, MD

Emory School of Medicine



Dr. Vickery is Professor of Pediatrics, Marcus Professor of Pediatric Immunology, and Chief of the Division of Allergy and Immunology at Emory University and Children's Healthcare of Atlanta. He is a nationally prominent clinician-scientist focused on improving outcomes for children with allergic disease through the development and implementation of interventions that effectively address unmet medical needs. Dr. Vickery has a 15+ year track record of sustained extramural funding, national service, mentorship, and scholarship in food allergy, work that has led to over 120 publications in leading journals and a current h-index of 39.

He received his undergraduate degree at the University of Georgia followed by a medical degree at the Medical College of Georgia. He then completed pediatric residency and chief residency at New York-Presbyterian Hospital/Weill Cornell Medical Center and fellowship at Yale University School of Medicine.

Yamini Vikas Virkud, MD, MA, MPH

University of North Carolina at Chapel Hill



Dr. Virkud is an assistant professor at the University of North Carolina at Chapel Hill (UNC) and adjunct faculty at Massachusetts General Hospital (MGH). She completed her medical training at Washington University in St. Louis, and concurrently obtained a master's degree in biology and biomedical sciences at Washington University. She completed her residency in pediatrics at St. Louis Children's Hospital and trained at Duke University for her fellowship in allergy and immunology, where she researched under the mentorship of Dr. Wesley Burks, exploring the safety of peanut oral immunotherapy for food allergy. During this time, she also completed a clinical research fellowship at Duke Clinical Research Institute and a Master of Public Health in Biostatistics at UNC. From 2014 to 2021, she was a faculty member at MGH and Harvard Medical School and became the director of Biostatistics and Data Management core of the MGH Food Allergy Center. In 2021, she joined the UNC Food Allergy Initiative. Her research focuses on the phenotyping of different patients with food allergy and understanding the mechanisms of investigational therapies for food allergy.

Paul Williams, MD

American Academy of Allergy, Asthma & Immunology



Dr. Williams is the current President of the American Academy of Allergy, Asthma & Immunology (AAAAI) and Clinical Professor of Pediatrics in the Allergy Division at the University of Washington School of Medicine. He retired in July 2021 after 31 years of private practice in allergy and immunology at Northwest Asthma & Allergy Center in Seattle. He is currently volunteering at a free clinic where he sees patients in their respiratory clinic. While practicing, his special interests included pediatric asthma, food allergy and chronic urticaria. In addition to practice, he also served on the University of Washington Fellowship committee, as director of the Seattle Children's Hospital resident allergy elective and participated in clinical research on asthma and food allergy. He has published over 50 articles in peer-reviewed journals and has been a speaker at national pediatric and allergy meetings.

Dr. Williams attended medical school at the University of Washington. He completed a pediatric residency and allergy/immunology fellowship at the University of Rochester and University of Washington, respectively.

Robert Wood, MD

Johns Hopkins University



Dr. Wood is a professor of pediatrics at Johns Hopkins University School of Medicine and a professor of international health at the Johns Hopkins Bloomberg School of Public Health. An internationally recognized expert in food allergy and childhood asthma, Dr. Wood is chief of the Eudowood Division of Allergy and Immunology in the Johns Hopkins Children's Center. He also serves as director and attending physician of the Pediatric Allergy Clinics at The Johns Hopkins Hospital and as director of the Pediatric Allergy Consultation Service.

Dr. Wood is a world-renowned expert in food allergy and childhood asthma and has published more than 200 manuscripts in scientific journals, including *The New England Journal of Medicine*, *JAMA*, *Pediatrics*, and *The Journal of Allergy and Clinical Immunology*, as well as three books and numerous book chapters. He is associate editor of *The Journal of Allergy and Clinical Immunology*, deputy editor of the journal *Pediatric Allergy and Immunology*, and was previously an associate editor of the *Annals of Allergy, Asthma & Immunology*. He has served on the board of directors of the American Board of Allergy and Immunology and the American Academy of Allergy, Asthma & Immunology, where he held positions as secretary-treasurer and president-elect.

Dr. Wood earned his medical degree from the University of Rochester School of Medicine and Dentistry. He completed both a three-year pediatrics residency—serving as chief resident the final year—and a pediatric allergy and immunology fellowship at The Johns Hopkins Hospital. Dr. Wood joined the Johns Hopkins faculty in 1988.



FARE (Food Allergy Research & Education) is the leading nonprofit organization engaged in food allergy education and advocacy—and the largest provider of charitable support for food allergy research in the U.S. FARE’s innovative education, advocacy, and research initiatives transform the future of food allergy through new and improved treatments and prevention strategies, effective policies and legislation, and novel approaches to managing the disease. FARE has invested almost \$190 million to support food allergy research, education, and advocacy. For more information, visit FoodAllergy.org.

Follow FARE on social media!



Thank You to Our Generous CDD Sponsors



Thank You to FARE’s Platinum Partner

